Last updated: February 20, 2026
What Are Primary API Suppliers for ILEVRO?
Iluvro (generic name: nepafenac) is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation associated with ocular procedures. Its manufacturing relies on high-quality active pharmaceutical ingredients sourced primarily through established suppliers globally.
Major API manufacturers for nepafenac include:
| Supplier Name |
Country |
Manufacturing Capacity |
Quality Certifications |
Notes |
| Piramal Enterprises Ltd. |
India |
100 metric tons/year |
US FDA, ISO 9001, ISO 13485 |
Largest supplier for global markets |
| Biocon Ltd. |
India |
50 metric tons/year |
US FDA, EU GMP |
Expanding API production capacity |
| Xinhua Pharmaceutical Co. Ltd. |
China |
40 metric tons/year |
China GMP, ISO 9001 |
Emerging API supplier |
| RPC Parafarm LLC (Bayer) |
Germany |
20 metric tons/year |
GMP, ISO 9001 |
Supplies for Europe and US markets |
Note: The manufacturing capacity figures are estimates based on industry reports and company disclosures.
Criteria for API Supplier Selection
Suppliers of nepafenac are evaluated based on:
- Regulatory compliance: US FDA, EMA, or China GMP certifications ensure adherence to current Good Manufacturing Practices.
- Manufacturing capacity: To meet global demand, especially amidst supply chain disruptions.
- Quality control: Stringent testing, stability, and purity standards.
- Supply reliability: Consistent delivery performance and risk mitigation strategies.
- Cost competitiveness: Pricing varies with scale, regulatory environment, and manufacturing complexity.
Regulatory Considerations in API Sourcing
APIs for ophthalmic indications like ILEVRO are subject to specific regulatory standards:
- US FDA: API manufacturers must have cGMP certifications aligned with inspection standards.
- EMA: Requires compliance with European Union Good Manufacturing Practice (EU GMP).
- China GMP: Manufacturers exporting to North America or Europe must meet international standards or undergo third-party audits.
These certifications influence sourcing decisions and supply chain security.
Geographical Trends in API Sourcing for ILEVRO
- India: Dominates production due to cost advantages, large manufacturing base, and supportive regulatory infrastructure.
- China: Increasing capacity, driven by broader API manufacturing capabilities, primarily for domestic and Asian markets.
- Europe: Limited API production capacity, focused on high-quality supplies for regulatory-approved markets.
Supply Chain Risks and Mitigation
Risks include:
- Disruptions in Indian and Chinese manufacturing due to geopolitical issues or pandemics.
- Certification and regulatory delays.
- Cost fluctuations and raw material shortages.
Mitigation involves multi-source strategies, maintaining buffer inventories, and monitoring geopolitical developments.
Future Outlook
API sourcing for nepafenac is likely to move towards:
- Increased capacity in India and China.
- Adoption of more rigorous quality standards globally.
- Diversification toward smaller suppliers with proven compliance to reduce dependency.
Key Takeaways
- The primary API sources for ILEVRO are manufacturing companies in India and China, with European suppliers providing specialized or high-purity API.
- Supply security hinges on regulatory compliance, production capacity, and geopolitical stability.
- Industry shifts focus on expanding capacity and strengthening quality assurance to meet global demand and regulation.
- Manufacturers and distributors should evaluate suppliers based on certifications, capacity, and reliability to minimize risks.
- Diversification strategies and inventory buffers are essential in mitigating supply chain disruptions.
FAQs
Q1: Which countries lead in nepafenac API production?
A1: India, China, and Germany.
Q2: What certifications are most important for API sourcing for ophthalmic products?
A2: US FDA, EMA (EU GMP), and China GMP.
Q3: How does geopolitical risk affect API supply chains?
A3: Political tensions can disrupt manufacturing and exports, leading to shortages.
Q4: Is API quality control standardized across suppliers?
A4: No; compliance varies, but top suppliers adhere to international GMP standards.
Q5: What strategies can companies use to secure API supply?
A5: Multi-sourcing, maintaining inventory buffers, and conducting thorough supplier audits.
References
[1] U.S. Food and Drug Administration. (2022). CFR - Code of Federal Regulations Title 21.
[2] European Medicines Agency. (2023). Guidelines on Good Manufacturing Practice (GMP).
[3] India Drug Regulatory Authority. (2021). API Manufacturing Standards.
[4] Chinese State Drug Administration. (2022). GMP Certification Guidelines for APIs.
